非小细胞肺癌抗血管生成治疗研究现状

doi:10.11904/j.issn.1002-3070.2017.05.017

摘要/Abstract

摘要： 血管生成是指从已有血管网络中生成新生血管的生理过程。在肿瘤微环境中,一个不断增长的肿瘤的动态平衡有利于转向持续促血管生成状态。自人类认识到可以通过抵抗肿瘤血管生成从而抑制肿瘤生长后,抗血管生成药物应运而生并已被应用在多种实体肿瘤中,包括肺癌。本文就肿瘤血管生成以及非小细胞肺癌抗血管生成的研究现状进行综述。

关键词: 抗血管生成, 非小细胞肺癌, 血管内皮生长因子, 酪氨酸激酶抑制剂

Abstract: Angiogenesis is the physiological process of generating new blood vessels from existing networks.In the tumor microenvironment,the dynamic balance of a growing tumor facilitates the transition to persistent angiogenesis.Antiangiogenic drugs have been used in a variety of solid tumors,including lung cancers,by resisting tumor angiogenesis and inhibiting tumor growth,since human recognized its ability.In this paper,recent research status of tumor angiogenesis and non-small cell lung cancer anti-angiogenesis are reviewed in details.

Key words: Anti-angiogenesis, Non-small cell lung cancer, VEGF, TKI

中图分类号:

R734.2

代欣综述, 张大昕审校. 非小细胞肺癌抗血管生成治疗研究现状[J]. 实用肿瘤学杂志, 2017, 31(5): 472-476.

DAI Xin, ZHANG Daxin. Current status of anti-angiogenesis therapy for non-small cell lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 472-476.

参考文献

1 Rogosin S,Sandler AB.Beyond bevacizumab:antiangiogenic agents[J].Clin Lung Cancer,2012,13(5):326-333.
2 Jayson GC,Kerbel R,Ellis LM,et al.Antiangiogenic therapy in oncology:current status and future directions[J].Lancet,2016,388(10043):518-529.
3 Chen Y,Li X,Yang H,et al.Expression of basic fibroblast growth factor,CD31,and α-smooth muscle actin and esophageal cancer recurrence after definitive chemoradiation[J].Tumor Biol,2014,35(7):7275-7282.
4 Braghiroli MI,Sabbaga J,Hoff PM.Bevacizumab:overview of the literature[J].Expert Rev Anticancer Ther,2012,12(5):567-580.
5 Folkman J,Klagsbrun M.A family of angiogenic peptides[J].Nature,1987,329(6141):671-672.
6 Folkman J.Tumor angiogenesis:therapeutic implications[J].N Engl J Med,1971,285(21):1182-1186.
7 Alvarez RH,Kantarjian HM,Cortes JE.Biology of platelet-derived growth factor and its involvement in disease.[J].Mayo Clin Pro,2006,81(9):1241-1257.
8 Ferrara N,Gerber HP,LeCouter J.The biology of VEGF and its receptors[J].Nat Med,2003,9(6):669-676.
9 Ellis LM,Hicklin DJ.VEGF-targeted therapy:mechanisms of anti-tumour activity[J].Nat Rev Cancer,2008,8(8):579-591.
10 Abdollahi A,Hahnfeldt P,Maercker C,et al.Endostatin's antiangiogenic signaling network[J].Mol Cell,2004,13(5):649-663.
11 Ballas MS,Chachoua A.Rationale for targeting VEGF,FGF,and PDGF for the treatment of NSCLC[J].Oncotargets Ther,2011,4(1):43-58.
12 Ebos JML,Kerbel RS.Antiangiogenic therapy:impact on invasion,disease progression,and metastasis[J].Nat Rev Clin Oncol,2011,8(4):210-221.
13 Li J,Dai CH,Chen P,et al.Survival and prognostic factors in small cell lung cancer[J].Med Oncol,2010,27(1):73-81.
14 Niho S,Kunitoh H,Nokihara H,et al.Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.[J].Lung Cancer,2012,76(3):362.
15 Zhou C,Wu YL,Chen G,et al.BEYOND:A randomized,double-Blind,placebo-controlled,multicenter,phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer[J].J Clin Oncol,2015,33(19):2197.
16 Poole RM,Vaidya A.Ramucirumab:first global approval[J].Drugs,2014,74(9):1047-1058.
17 Garon EB,Ciuleanu TE,Arrieta O,et al.Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy(REVEL):a multicentre,double-blind,randomised phase 3 trial[J].Lancet,2014,384(9944):665-673.
18 Asahina H,Tamura Y,Nokihara H,et al.An open-label,phase 1 study evaluating safety,tolerability,and pharmacokinetics of linifanib(ABT-869)in Japanese patients with solid tumors[J].Cancer Chemoth Pharm,2012,69(6):1477-1486.
19 Horinouchi H,Yamamoto N,Nokihara H,et al.A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer(NSCLC)[J].Cancer Chemoth Pharm,2014,74(1):37-43.
20 Ramalingam SS,Shtivelband M,Soo RA,et al.Randomized Phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer[J].J Clin Oncol,2015,33(5):433-441.
21 Van C E,Tabernero J,Lakomy R,et al.Addition of aflibercept to fluorouracil,leucovorin,and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen[J].J Clin Oncol,2012,30(28):3499-3506.
22 Chen H,Modiano MR,Neal JW,et al.A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer[J].Brit J Cancer,2014,110(3):602-608.
23 Ramlau R,Gorbunova V,Ciuleanu TE,et al.Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer:A randomized,controlled phase III trial[J].J Clin Oncol,2012,30(29):3640-3647.
24 Bottsford-Miller JN,Coleman RL,Sood AK.Resistance and escape from antiangiogenesis therapy:clinical implications and future strategies[J].J Clin Oncol,2012,30(32):4026-4034.
25 Spigel DR,Greco FA,Shipley DL,et al.Randomized,double-blind,placebo-controlled,phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer[J].J Clin Oncol,2011,29(18):2582-2589.
26 Novello S,Scagliotti GV,Rosell R,et al.Novello S,Scagliotti G V,Rosell R,et al.Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer[J].Clin Lung Cancer,2009,101(9):1543-1548.
27 Morinaga Y,Suga Y,Ehara S,et al.Combination effect of AC‐7700,a novel combretastatin A-4 derivative,and cisplatin against murine and human tumors in vivo[J].Cancer Sci,2003,94(2):200-204.
28 Von PJ,Gorbounova V,Reck M,et al.DISRUPT:A randomised phase 2 trial of ombrabulin(AVE8062)plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer[J].Lung Cancer,2014,85(2):224-229.
29 McKeage MJ,Pawel JV,Reck M,et al.Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer[J].Brit J Cancer,2008,99(12):2006-2012.
30 Lara PN,Douillard JY,Nakagawa K,et al.Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan(ASA404)in advanced non-small-cell lung cancer[J].J Clin Oncol,2011,29(22):2965-2971.
31 Ma T,Fuld AD,Rigas JR,et al.A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients[J].Chemotherapy,2012,58(4):321-329.
32 Folkman J.Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J].Exp Cell Res,2006,312(5):594-607.
33 DeRose P,Thorpe PE,Gerber DE.Development of bavituximab,a vascular targeting agent with immune-modulating properties,for lung cancer treatment[J].Immunotherapy,2011,3(8):933-44.
34 Digumarti R,Bapsy PP,Suresh AV,et al.Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer[J].Lung Cancer,2014,86(2):231-236.
35 Damaraju VL,Kuzma M,Mowles D,et al.Interactions of multitargeted kinase inhibitors and nucleoside drugs:Achilles heel of combination therapy?[J].Mol Cancer Ther,2015,14(1):236-245.
36 Moserle L,Jiménez-Valerio G,Casanovas O.Antiangiogenic therapies:going beyond their limits[J].Cancer Discov,2014,4(1):31-41.

[1]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[2]	李万祯, 殷俊, 李萍, 林晓辉, 张国前, 张书旭. iR-17在非小细胞肺癌放射抗拒细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(5): 391-397.
[3]	蔡静, 候玥. 非小细胞肺癌患者血清miR-195的表达及其临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 415-419.
[4]	崔晓燕, 涂青, 甘建辉. 纳布啡与羟考酮自控镇痛对非小细胞肺癌患者术后免疫因子水平影响的比较[J]. 实用肿瘤学杂志, 2018, 32(4): 309-314.
[5]	雷俊华, 许冠华, 曾江正, 黄芬, 何志惠, 卢彦达. 隐丹参酮联合顺铂抗非小细胞肺癌NCI-H1975细胞JAK2/STAT3机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 198-202.
[6]	翟可可, 高媛媛, 冯晓, 许静文, 宫玉芳, 孟庆威. 术后辅助化疗后复发转移与初次诊断的IV期NSCLC一线化疗疗效分析[J]. 实用肿瘤学杂志, 2018, 32(2): 107-111.
[7]	杜夜生, 胡松柳, 徐向英. 非小细胞肺癌寡转移的立体定向放射治疗研究[J]. 实用肿瘤学杂志, 2018, 32(2): 154-158.
[8]	孙明亮, 徐建宇, 徐向英. 早期非小细胞肺癌立体定向放疗的相关研究[J]. 实用肿瘤学杂志, 2018, 32(1): 53-56.
[9]	梁语丝, 谭永刚, 邹华伟审校. 低剂量化疗作用机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 538-542.
[10]	胡海峰, 冯谢敏, 乔健, 段伟, 刘宁宁, 孙晓东. miR-345在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2017, 31(2): 117-122.
[11]	张锐，王智煜，王帅，赵晖. 重组人血管内皮抑素联合NP方案治疗初诊晚期非小细胞肺癌骨转移疗效及对血清VEGF表达的影响[J]. 实用肿瘤学杂志, 2016, 30(6): 527-522.
[12]	任凤海,王丹丹,王俊峰,徐海,徐世东. 单孔与单操作孔电视辅助胸腔镜手术治疗ⅠA期非小细胞肺癌的临床对比研究[J]. 实用肿瘤学杂志, 2016, 30(4): 327-331.
[13]	王静, 封安强, 张南征. 天然14肽生长抑素联合5-Fu对胃癌移植瘤的抑制作用[J]. 实用肿瘤学杂志, 2016, 30(3): 214-219.
[14]	陈龙综述, 钱诚审校. 血管内皮生长因子基因多态性与乳腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 284-286.
[15]	叶磊光, 闫安, 刘宝刚. Aurora-A参与非小细胞肺癌化疗药耐药与患者预后的关系[J]. 实用肿瘤学杂志, 2016, 30(2): 97-102.